Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)

Sichuan Kelun Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	21,760	20,714	18,601	16,936	16,128	17,296
Other Revenue	739.64	739.64	437.62	341.23	336.6	340.31
Revenue	22,500	21,454	19,038	17,277	16,464	17,636
Revenue Growth (YoY)	7.96%	12.69%	10.19%	4.94%	-6.65%	7.86%
Cost of Revenue	10,855	10,291	9,084	7,993	7,866	7,064
Gross Profit	11,645	11,163	9,954	9,284	8,598	10,572
Selling, General & Admin	5,230	5,592	5,657	5,877	5,608	7,501
Research & Development	1,862	1,944	1,795	1,737	1,527	1,286
Other Operating Expenses	223.21	184.61	192.45	150.4	198.76	15.55
Operating Expenses	7,351	7,756	7,694	7,800	7,377	8,878
Operating Income	4,294	3,407	2,260	1,484	1,221	1,695
Interest Expense	-210.27	-361.54	-475.22	-518.34	-554.86	-584.83
Interest & Investment Income	316.15	462.47	278.81	244.03	125.2	200.27
Currency Exchange Gain (Loss)	33.36	33.36	-41.86	-2.31	-46.12	10.25
Other Non Operating Income (Expenses)	93.69	-21.28	-143.9	-21.84	-31.17	-48.57
EBT Excluding Unusual Items	4,527	3,520	1,878	1,186	713.63	1,272
Gain (Loss) on Sale of Investments	28.43	14.67	9.86	4.83	0.42	-
Gain (Loss) on Sale of Assets	1.6	2.63	5.4	-7.94	-20.04	-4.79
Asset Writedown	-42.53	-58.62	-1.93	-13.2	-11.24	-11.4
Other Unusual Items	225.62	101.95	177	8.38	272.26	0.64
Pretax Income	4,740	3,580	2,068	1,178	955.03	1,256
Income Tax Expense	1,316	933.79	363.7	309.5	163.55	234.75
Earnings From Continuing Operations	3,425	2,647	1,704	868.12	791.48	1,022
Minority Interest in Earnings	-460.9	-190.53	1.1	234.44	37.91	-83.69
Net Income	2,964	2,456	1,705	1,103	829.39	937.86
Net Income to Common	2,964	2,456	1,705	1,103	829.39	937.86
Net Income Growth	30.95%	44.03%	54.67%	32.94%	-11.57%	-22.68%
Shares Outstanding (Basic)	1,543	1,453	1,398	1,414	1,430	1,429
Shares Outstanding (Diluted)	1,566	1,545	1,483	1,414	1,430	1,429
Shares Change (YoY)	2.14%	4.17%	4.91%	-1.15%	0.05%	0.15%
EPS (Basic)	1.92	1.69	1.22	0.78	0.58	0.66
EPS (Diluted)	1.89	1.59	1.15	0.78	0.58	0.66
EPS Growth	28.20%	38.26%	47.44%	34.48%	-11.61%	-22.80%
Free Cash Flow	2,412	3,568	2,230	1,857	988.5	885.7
Free Cash Flow Per Share	1.54	2.31	1.50	1.31	0.69	0.62
Dividend Per Share	1.060	0.800	0.616	0.426	0.319	0.425
Dividend Growth	72.08%	29.87%	44.60%	33.63%	-24.99%	102.77%
Gross Margin	51.76%	52.03%	52.28%	53.74%	52.22%	59.95%
Operating Margin	19.09%	15.88%	11.87%	8.59%	7.41%	9.61%
Profit Margin	13.17%	11.45%	8.96%	6.38%	5.04%	5.32%
Free Cash Flow Margin	10.72%	16.63%	11.71%	10.75%	6.00%	5.02%
EBITDA	5,488	4,585	3,416	2,690	2,375	2,765
EBITDA Margin	24.39%	21.37%	17.94%	15.57%	14.43%	15.68%
D&A For EBITDA	1,194	1,178	1,156	1,206	1,155	1,070
EBIT	4,294	3,407	2,260	1,484	1,221	1,695
EBIT Margin	19.09%	15.88%	11.87%	8.59%	7.41%	9.61%
Effective Tax Rate	27.76%	26.08%	17.59%	26.28%	17.13%	18.69%
Revenue as Reported	22,500	21,454	19,038	17,277	16,464	-
Advertising Expenses	-	265.58	129.59	161.8	1.78	-

Source: S&P Capital IQ. Standard template. Financial Sources.